Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 10, 2007, Pages 1305-1312

  Wang, Sihe ^a,b   Vicente, Faye B ^a   Miller, Alan ^a   Brooks, Ellen R ^a   Price, Heather E ^a   Smith, Frederick A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Arginine; Asymmetric dimethylarginine; HPLC; Mass spectrometry; Symmetric dimethylarginine

Indexed keywords

ARGININE DERIVATIVE; CARBON; N(G),N(G) DIMETHYLARGININE;

AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SEX RATIO; SIBLING; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIBLINGS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 35048878172     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.277     Document Type: Article

References (33)

1. Nijveldt RJ, Siroen MP, Teerlink T, van Leeuwen PA. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure? J Nutr 2004;134:2848S-52S.
2. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
3. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000;20:2032-7.
4. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction - its role in hypercholesterolemia. Circulation 1998;98:1842-7.
5. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005;80:1660-6.
6. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger M, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003;57:244-52.
7. Sahin M, Arslan C, Naziroglu M, Tunc SE, Demirci M, Sutcu R, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci 2006;36:449-54.
8. Sydow K, Hornig B, Arakawa N, Bode-Boger SM, Tsikas D, Munzel T, et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 2004;9:93-101.
9. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia - role of asymmetric dimethylarginine. Circulation 2003;108:933-8.
10. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT. Relation of improvement in endothelium-dependent flow-mediated vasodilation after Rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006;98:1057-62.
11. Zoccali C, Mallamaci F, Tripepi G. Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in endstage renal disease (ESRD). Eur J Clin Pharmacol 2006;62:131-5.
12. Zoccali C, Bode-Boger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
13. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-45.
14. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (s-VCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005;68:2230-6.
15. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005;16:2449-55.
16. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61.
17. Caglar K, Yilmaz ML, Sonmez A, Cakir E, Kaya A, Acikel C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-7.
18. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006;17:1128-34.
19. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005;10:S89-S95.
20. Martens-Lobenhoffer J, Westphal S, Awiszus F, Bode-Boger SM, Luley C. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem 2005;51:2188-9.
21. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Biomed Sci Appl 2005;828:97-102.
22. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268-71.
23. Martens-Lobenhoffer J, Bode-Boger SM. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B Biomed Sci Appl 2003;798:231-9.
24. Martens-Lobenhoffer J, Krug O, Bode-Boger SM. Determination of arginine and asymmetric dimethylarginine (ADMAL) in human plasma by liquid chromatography/ mass spectrometry with the isotope dilution technique. J Mass Spectrom 2004;39:1287-94.
25. Huang LF, Guo FQ, Liang YZ, Hu QN, Cheng BM. Rapid simultaneous determination of arginine and methylated arginines in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chim Acta 2003;487:145-53.
26. Kirchherr H, Kuhn-Velten WN. HPLC-tandem mass spectrometric method for rapid quantification of dimethylarginines in human plasma. Clin Chem 2005;51:249-52.
27. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. Determination of arginine and methylated arginines in human plasma by liquid chromatography- tandem mass spectrometry. J Chromatogr B Biomed Appl 2000;748:157-66.
28. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatographyelectrospray tandem mass spectrometry. Clin Chem 2006;52:488-93.
29. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
30. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005;10:S11-7.
31. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J 2006;152:493.e1-e8.
32. Lenzen H, Tsikas D, Boger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006;62:45-9.
33. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2007;53:273-83.